Glenmark Pharmaceuticals has announced the upcoming launch of Sodium Phosphates Injection USP in multiple single-dose vial presentations, further strengthening its institutional product portfolio in the North American market.
The company will introduce Sodium Phosphates Injection USP in 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) single-dose vials, with distribution scheduled to begin in April 2026.
Glenmark’s product is bioequivalent and therapeutically equivalent to the reference listed drug, Sodium Phosphates Injection USP, 45 mM P/15 mL (3 mM P/mL), of Hospira, Inc. The additional 15 mM P/5 mL and 150 mM P/50 mL presentations are expected to deliver the same therapeutic effect as the listed drug product relied upon by the US Food and Drug Administration for safety and effectiveness.
Strengthening Institutional Portfolio
The launch underlines Glenmark’s continued focus on expanding its presence in the institutional channel, particularly within hospital and acute care settings where injectable products play a critical role in patient management.
According to IQVIA sales data for the 12-month period ending December 2025, the combined market for Sodium Phosphates Injection USP in the approved strengths recorded annual sales of approximately $66.8 million, reflecting steady demand in the segment.
Glenmark president and business head, North America Marc Kikuchi said the launch aligns with the company’s strategy of delivering high-quality, affordable alternatives while broadening its injectable portfolio. He noted that the addition reinforces Glenmark’s commitment to serving healthcare providers and patients with reliable therapeutic options.
Expanding The US Footprint
With this introduction, Glenmark continues to deepen its US generics portfolio, focusing on products that support hospital procurement channels and address essential care requirements. The new Sodium Phosphates Injection presentations are approved only for the indications listed in Glenmark’s FDA-approved labelling.
As the company advances its North American growth strategy, the launch represents another step in reinforcing its institutional footprint and enhancing its competitive positioning in the injectable generics market.